TABLE 2.
Bacterial features, β-lactam susceptibilities, results of carbapenemase-detection methods, and KPC variantsa
| Patient | Isolate | 2021 date (mo-day) |
Sourceb | Antimicrobial susceptibilityc (MIC in mg/L/interpretation) |
KPC detectiond |
KPC-variant | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DD-PBA, BCA, MHT | LFIA | MALDI-TOF MS | |||||||||||||||
| CZA | MEM | IPM | ETP | FEP | CAZ | CRO | TZP | SAM | FOX | ||||||||
| 1 | 1A | 04-04 | R | 1/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 |
| 1B | 04-04 | U | 1/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 | |
| 1C | 04-15 | C | >256/R | ≤0.5/S | ≤0.25/S | >1/R | 16/R | >16/R | >4/R | 16/S | 16/I | ≤4/S | – | – | + | 31 | |
| 2 | 2A | 06-06 | R | >256/R | ≤0.5/S | ≤0.25/S | >1/R | 16/R | >16/R | >4/R | 2/S | 16/I | ≤4/S | – | – | + | 31 |
| 3 | 3A | 06-08 | B | >256/R | ≤0.5/S | 1/S | >1/R | 16/R | >16/R | >4/R | 8/S | 16/I | ≤4/S | – | – | + | 31 |
| 4 | 4A | 06-24 | U | >256/R | ≤0.5/S | ≤0.25/S | >1/R | 16/R | >16/R | >4/R | 2/S | 16/I | 8/S | – | – | + | 31 |
| 5 | 5A | 06-20 | C | 1/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 |
| 5B | 06-25 | R | 1/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 | |
| 5C | 07-03 | R | 1/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 | |
| 5D | 07-03 | C | 1/S | 8/R | 8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | 16/I | + | + | + | 3 | |
| 5E | 07-03 | B | 1/S | 8/R | 8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | 16/I | + | + | + | 3 | |
| 5F | 07-15 | B | 24/R | ≤0.5/S | ≤0.25/S | 0.5/S | 2/S | >16/R | >4/R | ≤4/S | >16/R | ≤4/S | – | + | + | 115 | |
| 6 | 6A | 06-19 | R | 2/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 |
| 6B | 06-25 | B | 2/S | >32/R | >8/R | >1/R | >16/R | >16/R | >4/R | >64/R | >16/R | >16/R | + | + | + | 3 | |
| 6C | 07-20 | B | 64/R | ≤0.5/S | ≤0.25/S | >1/R | 16/R | >16/R | >4/R | 8/S | >16/R | ≤4/S | – | – | + | 31 | |
a
Ceftazidime-avibactam-resistant isolates are shown in bold.
b
Sources: R, respiratory; U, urine; C, catheter; B, blood.
c
Antimicrobials: CZA, ceftazidime-avibactam; MEM, meropenem; IPM, imipenem; ETP, ertapenem; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; TZP, piperacillin-tazobactam; SAM, ampicillin-sulbactam; FOX, cefoxitin.
d
KPC detection: DD-PBA, double disk diffusion with phenyl-boronic acid; BCA, BlueCarba assay; MHT, modified Hodge test; LFIA, lateral flow immunoassay; MALDI-TOF MS, use of this technology for detection of mature KPC protein.